Business Wire

American Express Reveals 2023 Top Travel Trends

23.3.2023 16:00:00 EET | Business Wire | Press release

Share

American Express Travel® released their 2023 Global Travel Trends Report today, highlighting four global trends inspiring people to travel this year:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005091/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

American Express Travel's 2023 Global Travel Trends Report

  • The Rise of “Set-Jetting”: Popular movies, TV shows and social media are inspiring people to travel to places they see onscreen, like Italy, Paris, Yellowstone, and London
  • Delicious Destinations: From top restaurants to local favorites to cooking classes, people are choosing their next destination based on what they’ll eat
  • A Wellness Wave: Restorative vacations are on the rise as travelers prioritize self-care and mental and physical health
  • Traveling Off the Beaten Path: Travelers want to discover hidden gems and support the local community when they visit

The report, based on survey data from travelers from the United States, Australia, Canada, Mexico, Japan, India and the United Kingdom, found that more than half (52%) of respondents say they plan to take more trips this year than last year and 50% of respondents are planning to spend more money on travel in 2023 than 2022. 84% of Gen Z and Millennials surveyed would rather take a dream vacation than purchase a new luxury item, and 79% agree that travel is an important budget priority.

“Vacations are precious, and travelers are prioritizing personalized itineraries built around their passions, from planning an entire vacation for a single dinner reservation to getting the perfect video for TikTok,” says Audrey Hendley, President of American Express Travel. “No matter what the inspiration is, American Express Travel Consultants have the expertise to help every type of traveler plan all types of trips.”

Top insights from American Express Travel’s 2023 Global Travel Trends Report include:

  • Pop culture and social media are influencing the rise of “set-jetting,” especially among younger travelers.
    • 75% of respondents agree that they have been inspired to travel to a specific destination by social media
    • 70% of Gen Z and Millennials surveyed agree that they have been inspired to visit a destination after seeing it featured in a TV show, news source, or movie
    • 46% of Gen Z and Millennials surveyed say they have been inspired to travel to a destination because of Instagram

  • From visiting top restaurants and local favorites to taking a cooking class, food has a huge impact on where people travel.
    • 81% of respondents agree that trying local foods and cuisines is the part of traveling they look forward to the most
    • 66% of Gen Z and Millennials surveyed agree that they get most of their eating-while-traveling inspiration from social media
    • Nearly half (47%) of Gen Z and Millennials surveyed agree that they have planned an entire trip around visiting a specific restaurant

  • Prioritizing self-care is leading to a rise in restorative vacations.
    • 73% of respondents are planning vacations to better their mental, physical, and emotional health this year
    • 60% of Gen Z and Millennials surveyed say they go out of their way to book hotels that offer spa and wellness services

  • Travelers want to discover hidden gems and support the local communities they visit.
    • 85% of respondents want to visit a place where they can truly experience the local culture
    • 78% of respondents are interested in going on vacations that support local communities in 2023

As the demand for travel continues into 2023, American Express Travel provides eligible Card Members with exceptional travel access, including 1,400+ airport lounges through its Global Lounge Collection; 7,000+ Travel Consultants; restaurant reservations through Resy and curated where-to-eat guides at Resy.com/Travel; benefits at 2,000+ hand-picked hotels around the world via Fine Hotels + Resorts® and The Hotel Collection; and more.

The full American Express Travel 2023 Global Travel Trends Report can be viewed here.

ABOUT AMERICAN EXPRESS

American Express is a globally integrated payments company, providing customers with access to products, insights and experiences that enrich lives and build business success. Learn more at americanexpress.com and connect with us on facebook.com/americanexpress, instagram.com/americanexpress, linkedin.com/company/american-express, twitter.com/americanexpress, and youtube.com/americanexpress.

Key links to products, services and corporate responsibility information: personal cards, business cards and services, travel services, gift cards, prepaid cards, merchant services, Accertify, Kabbage , Resy, corporate card, business travel, diversity and inclusion, corporate responsibility and Environmental, Social, and Governance reports.

Methodology:

1The American Express 2023 Global Travel Trends Report is based on data obtained through an online poll conducted by Morning Consult between February 3rd – 11th, 2023 among a sample of 1,000 travelers from Australia, Canada, India, Japan, Mexico, UK and 2,000 travelers in the US who have a household income of at least a $70k equivalent, and who typically travel by air at least once a year. Results from each market’s survey have a margin of error of plus or minus 3 percentage points.

2Gen Z and Millennials are defined as respondents as being born between 1981 - 2012.

Seller of Travel

American Express Travel Related Services Company, Inc. is acting solely as a sales agent for travel suppliers and is not responsible for the actions or inactions of such suppliers. Certain suppliers pay us commission and other incentives for reaching sales targets or other goals and may provide incentives to our Travel Consultants. For more information visit www.americanexpress.com/travelterms.

California CST#1022318; Washington UBI#600-469-694

Source: American Express Company

Location: New York

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

AMERICAN EXPRESS
Emily Vicker
Emily.Vicker@aexp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye